Published in Development on December 18, 2013
Dephosphorylation and inactivation of NPR2 guanylyl cyclase in granulosa cells contributes to the LH-induced decrease in cGMP that causes resumption of meiosis in rat oocytes. Development (2014) 1.54
Pathophysiology and the cardiorenal connection in heart failure. Circulating hormones: biomarkers or mediators. Clin Chim Acta (2014) 0.81
Impaired sinoatrial node function and increased susceptibility to atrial fibrillation in mice lacking natriuretic peptide receptor C. J Physiol (2015) 0.80
Systemic, but not cardiomyocyte-specific, deletion of the natriuretic peptide receptor guanylyl cyclase A increases cardiomyocyte number in neonatal mice. Histochem Cell Biol (2015) 0.78
Harnessing the Induction of Cardiomyocyte Proliferation for Cardiac Regenerative Medicine. Curr Treat Options Cardiovasc Med (2015) 0.78
Functional properties of bone marrow derived multipotent mesenchymal stromal cells are altered in heart failure patients, and could be corrected by adjustment of expansion strategies. Aging (Albany NY) (2015) 0.78
Pharmacological Therapy in the Heart as an Alternative to Cellular Therapy: A Place for the Brain Natriuretic Peptide? Stem Cells Int (2016) 0.76
Ablation of periostin inhibits post-infarction myocardial regeneration in neonatal mice mediated by the phosphatidylinositol 3 kinase/glycogen synthase kinase 3β/cyclin D1 signalling pathway. Cardiovasc Res (2017) 0.75
Innovative Therapeutics: Designer Natriuretic Peptides. JACC Basic Transl Sci (2016) 0.75
Tet-mediated DNA hydroxymethylation regulates retinal neurogenesis by modulating cell-extrinsic signaling pathways. PLoS Genet (2017) 0.75
High-resolution in situ hybridization to whole-mount zebrafish embryos. Nat Protoc (2008) 10.25
p53 activation by knockdown technologies. PLoS Genet (2007) 6.85
A new natriuretic peptide in porcine brain. Nature (1988) 4.22
Rapid transition of cardiac myocytes from hyperplasia to hypertrophy during postnatal development. J Mol Cell Cardiol (1996) 4.11
The cardiac homeobox gene Csx/Nkx2.5 lies genetically upstream of multiple genes essential for heart development. Development (1999) 3.74
Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science (1995) 3.61
Atrial natriuretic factor: a hormone produced by the heart. Science (1985) 3.07
Targeting neural circuitry in zebrafish using GAL4 enhancer trapping. Nat Methods (2007) 3.00
Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad Sci U S A (1997) 2.99
Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A (2000) 2.58
The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. Proc Natl Acad Sci U S A (1999) 2.48
Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J Clin Invest (2003) 2.37
Localized expression of the atrial natriuretic factor gene during cardiac embryogenesis. Genes Dev (1987) 2.24
Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology (1992) 2.06
Neonatal atria and ventricles secrete atrial natriuretic factor via tissue-specific secretory pathways. Cell (1986) 1.98
Deletion of GSK-3beta in mice leads to hypertrophic cardiomyopathy secondary to cardiomyoblast hyperproliferation. J Clin Invest (2008) 1.76
Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. J Biol Chem (2003) 1.60
Mef2cb regulates late myocardial cell addition from a second heart field-like population of progenitors in zebrafish. Dev Biol (2011) 1.31
Cardiac hypertrophy in transgenic rats expressing a dominant-negative mutant of the natriuretic peptide receptor B. Proc Natl Acad Sci U S A (2006) 1.18
In vivo monitoring of cardiomyocyte proliferation to identify chemical modifiers of heart regeneration. Development (2013) 1.15
Cellular mechanisms of the clearance function of type C receptors of atrial natriuretic factor. J Biol Chem (1990) 1.11
Cytoplasmic domain of natriuretic peptide receptor-C inhibits adenylyl cyclase. Involvement of a pertussis toxin-sensitive G protein. J Biol Chem (1996) 1.04
Identification of the G protein-activating domain of the natriuretic peptide clearance receptor (NPR-C). J Biol Chem (1999) 1.03
Developmental expression of myostatin in cardiomyocytes and its effect on foetal and neonatal rat cardiomyocyte proliferation. Cardiovasc Res (2007) 0.98
Tissue inhibitor of metalloproteinase-3 inhibits neonatal mouse cardiomyocyte proliferation via EGFR/JNK/SP-1 signaling. Am J Physiol Cell Physiol (2009) 0.96
Dendroaspis natriuretic peptide binds to the natriuretic peptide clearance receptor. Biochem Biophys Res Commun (2007) 0.96
Natriuretic peptide receptor-3 underpins the disparate regulation of endothelial and vascular smooth muscle cell proliferation by C-type natriuretic peptide. Br J Pharmacol (2011) 0.95
Distinct regulation of developmental and heart disease-induced atrial natriuretic factor expression by two separate distal sequences. Circ Res (2008) 0.92
Natriuretic peptides stimulate the cardiac sodium pump via NPR-C-coupled NOS activation. Am J Physiol Cell Physiol (2008) 0.89
Atrial natriuretic peptide inhibits angiotensin II-stimulated proliferation in fetal cardiomyocytes. J Physiol (2010) 0.89
Influence of natriuretic peptide receptor-1 on survival and cardiac hypertrophy during development. Biochim Biophys Acta (2009) 0.87
The discovery of non-basic atrial natriuretic peptide clearance receptor antagonists. Part 1. Bioorg Med Chem Lett (2000) 0.85
C-type natriuretic peptide has a negative inotropic effect on cardiac myocytes. Eur J Pharmacol (2001) 0.81
Knockdown of natriuretic peptide receptor-A enhances receptor C expression and signalling in vascular smooth muscle cells. Cardiovasc Res (2011) 0.81
Paradoxical antagonism of PACAP receptor signaling by VIP in Xenopus oocytes via the type-C natriuretic peptide receptor. Cell Signal (2006) 0.78
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet (2009) 12.19
The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies. BMC Med Genomics (2011) 9.20
Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature (2007) 8.03
Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med (2008) 7.13
PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations. Bioinformatics (2010) 7.07
Robust replication of genotype-phenotype associations across multiple diseases in an electronic medical record. Am J Hum Genet (2010) 6.44
Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med (2014) 4.94
Implementing genomic medicine in the clinic: the future is here. Genet Med (2013) 4.89
Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. Nat Biotechnol (2013) 4.85
The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future. Genet Med (2013) 4.37
Concern Calmodulin kinase II and arrhythmias in a mouse model of cardiac hypertrophy. Circulation (2002) 4.16
Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia. J Clin Invest (2006) 4.06
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood (2008) 4.02
Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet (2010) 3.97
A rare variant in MYH6 is associated with high risk of sick sinus syndrome. Nat Genet (2011) 3.94
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. N Engl J Med (2016) 3.88
Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy. Nat Genet (2004) 3.88
Variants near FOXE1 are associated with hypothyroidism and other thyroid conditions: using electronic medical records for genome- and phenome-wide studies. Am J Hum Genet (2011) 3.85
Principles of human subjects protections applied in an opt-out, de-identified biobank. Clin Transl Sci (2010) 3.84
Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet (2012) 3.71
Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med (2009) 3.35
Identification of genomic predictors of atrioventricular conduction: using electronic medical records as a tool for genome science. Circulation (2010) 3.35
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet (2013) 3.21
Fossil steroids record the appearance of Demospongiae during the Cryogenian period. Nature (2009) 3.06
Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation (2002) 2.98
Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop. Circulation (2010) 2.94
KCNH2-K897T is a genetic modifier of latent congenital long-QT syndrome. Circulation (2005) 2.78
An isogenetic myoblast expression screen identifies DUX4-mediated FSHD-associated molecular pathologies. EMBO J (2008) 2.74
Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. Circulation (2008) 2.72
Common sodium channel promoter haplotype in asian subjects underlies variability in cardiac conduction. Circulation (2006) 2.72
C/EBPβ controls exercise-induced cardiac growth and protects against pathological cardiac remodeling. Cell (2010) 2.68
High-throughput assay for small molecules that modulate zebrafish embryonic heart rate. Nat Chem Biol (2005) 2.64
Polymorphism modulates symptomatic response to antiarrhythmic drug therapy in patients with lone atrial fibrillation. Heart Rhythm (2007) 2.62
Blocking Scn10a channels in heart reduces late sodium current and is antiarrhythmic. Circ Res (2012) 2.61
Chemical suppression of a genetic mutation in a zebrafish model of aortic coarctation. Nat Biotechnol (2004) 2.57
Cardiac sodium channel (SCN5A) variants associated with atrial fibrillation. Circulation (2008) 2.56
Drug-induced long QT syndrome. Pharmacol Rev (2010) 2.55
Familial aggregation in lone atrial fibrillation. Hum Genet (2005) 2.55
Sodium channel β1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. J Clin Invest (2008) 2.54
Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation (2010) 2.49
Drugs that induce repolarization abnormalities cause bradycardia in zebrafish. Circulation (2003) 2.42
Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol (2010) 2.41
Defining the cellular phenotype of "ankyrin-B syndrome" variants: human ANK2 variants associated with clinical phenotypes display a spectrum of activities in cardiomyocytes. Circulation (2007) 2.38
Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov (2007) 2.32
Unmasking of brugada syndrome by lithium. Circulation (2005) 2.30
Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol (2006) 2.29
Locus for atrial fibrillation maps to chromosome 6q14-16. Circulation (2003) 2.28
Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy. Circulation (2003) 2.28
Klf2 is an essential regulator of vascular hemodynamic forces in vivo. Dev Cell (2006) 2.26
Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. J Am Coll Cardiol (2010) 2.17
The regenerative capacity of zebrafish reverses cardiac failure caused by genetic cardiomyocyte depletion. Development (2011) 2.11
Assessing the accuracy of observer-reported ancestry in a biorepository linked to electronic medical records. Genet Med (2010) 2.09
Genome- and phenome-wide analyses of cardiac conduction identifies markers of arrhythmia risk. Circulation (2013) 2.06
Large scale replication and meta-analysis of variants on chromosome 4q25 associated with atrial fibrillation. Eur Heart J (2009) 2.06
Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol (2004) 2.05
Drug-induced long QT and torsade de pointes: recent advances. Curr Opin Cardiol (2007) 2.04
Notch1b and neuregulin are required for specification of central cardiac conduction tissue. Development (2006) 2.00
Glucose-6-phosphate dehydrogenase modulates cytosolic redox status and contractile phenotype in adult cardiomyocytes. Circ Res (2003) 1.99
Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood (2008) 1.99
RBM20, a gene for hereditary cardiomyopathy, regulates titin splicing. Nat Med (2012) 1.97
The Use of Opioid Analgesics following Common Upper Extremity Surgical Procedures: A National, Population-Based Study. Plast Reconstr Surg (2016) 1.94
Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org). Heart Rhythm (2009) 1.92
Pattern recognition: combining informatics and genetics to re-evaluate conduction disease. Heart (2012) 1.91
Thymosin beta4 mediated PKC activation is essential to initiate the embryonic coronary developmental program and epicardial progenitor cell activation in adult mice in vivo. J Mol Cell Cardiol (2009) 1.88
Fine mapping of the 1p36 deletion syndrome identifies mutation of PRDM16 as a cause of cardiomyopathy. Am J Hum Genet (2013) 1.87
Prospective, population-based long QT molecular autopsy study of postmortem negative sudden death in 1 to 40 year olds. Heart Rhythm (2010) 1.87
Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. Nat Genet (2013) 1.86
Genetic variation in the alternative splicing regulator RBM20 is associated with dilated cardiomyopathy. Heart Rhythm (2011) 1.85
Mice with the R176Q cardiac ryanodine receptor mutation exhibit catecholamine-induced ventricular tachycardia and cardiomyopathy. Proc Natl Acad Sci U S A (2006) 1.85
When good drugs go bad. Nature (2007) 1.85
Echocardiographic evaluation in asymptomatic relatives of patients with dilated cardiomyopathy reveals preclinical disease. Ann Intern Med (2005) 1.85
Chromosome 4q25 variants are genetic modifiers of rare ion channel mutations associated with familial atrial fibrillation. J Am Coll Cardiol (2012) 1.84
A calcium sensor in the sodium channel modulates cardiac excitability. Nature (2002) 1.83
Nkx2-5 mutation causes anatomic hypoplasia of the cardiac conduction system. J Clin Invest (2004) 1.80
Mutation in the transcriptional coactivator EYA4 causes dilated cardiomyopathy and sensorineural hearing loss. Nat Genet (2005) 1.80
In vivo recording of adult zebrafish electrocardiogram and assessment of drug-induced QT prolongation. Am J Physiol Heart Circ Physiol (2006) 1.77
Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood (2011) 1.77
Prolonged signal-averaged P-wave duration as an intermediate phenotype for familial atrial fibrillation. J Am Coll Cardiol (2008) 1.77
Novel KCNA5 mutation implicates tyrosine kinase signaling in human atrial fibrillation. Heart Rhythm (2010) 1.77
Plasminogen activator inhibitor-1 as a predictor of postoperative atrial fibrillation after cardiopulmonary bypass. Circulation (2007) 1.73
Identification of heart rate-associated loci and their effects on cardiac conduction and rhythm disorders. Nat Genet (2013) 1.72
The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome. J Clin Invest (2008) 1.69
Mutant desmocollin-2 causes arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet (2006) 1.68
C-Reactive protein in lone atrial fibrillation. Am J Cardiol (2006) 1.68
Cardiac sodium channel gene variants and sudden cardiac death in women. Circulation (2007) 1.67
Facilitating pharmacogenetic studies using electronic health records and natural-language processing: a case study of warfarin. J Am Med Inform Assoc (2011) 1.67
Factors affecting the degree of QT prolongation with drug challenge in a large cohort of normal volunteers. Heart Rhythm (2011) 1.66
Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record. Pharmacogenomics (2012) 1.66
Development of the cardiac conduction system as delineated by minK-lacZ. J Cardiovasc Electrophysiol (2003) 1.65
Calmodulin kinase II activity is required for normal atrioventricular nodal conduction. Heart Rhythm (2005) 1.63